Its a healthy morning as Novo Nordisk says sales of its obesity drug, Wegovy, rose 57% last year while Brits are buying more ...
MarketWatch on MSN9d
This Wegovy user spent $5,000 on a new wardrobe after losing 80 pounds — and she’s not aloneTori Allen says she’s thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more ...
Adani Wilmar is expecting an around 10% growth in sales volume next fiscal year, CEO Angshu Mallick told Reuters on Wednesday ...
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
A rising number of people have accepted GLP-1s as a way to treat obesity, which affects more than 100 million Americans.
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this area, Wegovy, to shame. Let's look deeper into these ...
丹麦制药巨头 诺和诺德 ( 82.8, -1.65, -1.95%) （Novo Nordisk）周三公布，由于其Wegovy减肥药需求飙升，第四季度净利润好于预期。
Demand for weight loss jabs continues to surge, particularly as the NHS began offering Wegovy in late 2023 and will start offering Mounjaro to patients in March 2025. They have also become ...
Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback